Biomerica Inc. (NASDAQ: BMRA) has entered an exclusive 5-years distribution deal with a Canadian company to market and distribute its novel Helicobacter Pylori test, hp+detect.
Biomerica to market hp+detect device in Canada
The company has developed the hp+detect device for identifying and monitoring Helicobacter Pylori infection, which is the leading cause of gastric and duodenal ulcers and a risk factor related to gastric cancer. Medical centers and physicians can use hp+detect in diagnosing Helicobacter Pylori and monitoring treatment efficacy.
To sell the device in Canada, the company’s distribution partner has to seek Health Canada’s approval through the clinical data Biomerica recently generated using hp+detect. In addition, Biomerica is seeking a CE mark for hp+detect to be available in the EU and FDA clearance for sale in the US.
Biomerica CEO and Chairman Zack Irani said, “We’re pleased to enter into this relationship with a well-established medical distributor in Canada. This partnership will be our first step to launching the hp+detect™ test in markets around the world to assist gastroenterologists and other medical professionals who are dedicated to preventing ulcers and gastric cancer in the patients they treat.”
Biomerica receives patent for InFoods tech platform in Mexico
The company received a notice of allowance from the Mexican Patent Office for its patent application regarding its InFoods tech platform that provides a novel treatment approach for Irritable Bowel Syndrome (IBS) patients. The patent claims cover the method enabling physicians to identify particular foods such as shrimp, milk, and broccoli, among others, that may alleviate IBS symptoms when removed from the diet.
Irani said, “We’re excited to have received this allowed patent in Mexico which provides broad protection around tests and methods used to determine patient-specific foods that may trigger IBS symptoms, and includes additional claims that cover a diagnostic-guided therapy for IBS patients.”
